Compare iShares MSCI Germany (DAX) (EWG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs TG Therapeutics Inc — how do they compare? iShares MSCI Germany (DAX) trades at $41.22, while TG Therapeutics Inc trades at $54.82 (market cap $8.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals.
| EWG | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $59.06 |
52-Week Low | $38.08 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $41.19, down 0.48% on the day with a neutral technical signal. The stock shows mixed technical indicators with bearish moving averages but oversold RSI conditions. Recent German economic developments, including a €13.3 billion energy relief package and healthcare reforms, create a complex backdrop for this US-listed German-focused ETF.
The outlook remains balanced with European monetary policy uncertainty and energy market volatility presenting both opportunities and risks. German fiscal support measures could provide stability, while ECB rate decisions and Middle East tensions may drive near-term volatility in European markets.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
